RECOFOL ® propofol satisfying anaesthesia & ICU sedation
RECOFOL active ingredient is propofol, which is the most widely used intravenous anaesthetic with growing global demand.
RECOFOL® – 1st branded generic Propofol
Intravenous anaesthetic, which is used by intensive care units, surgeries and clinics. RECOFOL® can be used from light sedation to total anaesthesia.
RECOFOL® active ingredient is propofol, which is the most widely used intravenous anaesthetic with growing global demand.
Primex is expanding RECOFOL® geographically with regional partners.
Recofol N® and Recofol EDTA®
Refocol N®
Recofol N® is a Bayer-originated intravenous anaesthetic, which is used by intensive care units, surgeries and clinics.
Primex Pharmaceuticals obtained Recofol N® through an acquisition from Bayer in 2011. Recofol N’s active ingredient is propofol.
Recofol N® is manufactured in Europe.
Refocol EDTA®
Recofol EDTA® (propofol plus EDTA) is propofol with the preservative EDTA as an antimicrobial retardant, as required by the FDA and other authorities and is manufactured in EU.
Existing Primex product portfolio
OZALIN / OZASED®* (2mg/ml oral midazolam solution)
• ADV6209 was the former name of the product.
• Licensed and approved for paediatric premedication and procedural sedation in the EU, UK and CH.
OGNA® Dental Portfolio
• Local Anaesthetic Portfolio – articaine, mepivicaine and lidocaine (spray & gel).
• Endodontic Medical Devices (CE marked).
